Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03431090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Jan 2026 to Dec 2026
    v10
  2. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Dec 2024 to Jan 2026
    v9
  3. Primary and study completion dates: Dec 2022 to Dec 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  4. Primary and study completion dates: Dec 2021 to Dec 2022v7
  5. Eligibility criteria shortened, about 32 words
    • Site contact updated
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Start date changed from estimate of May 2018 to Mar 2, 2018v4
  3. Start date: Apr 2018 to May 2018v3
  4. Start date: Feb 2018 to Apr 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.
Trial Details
NCT Number NCT03431090
Lead Sponsor Nationwide Children's Hospital
Conditions
(from sponsor)		 Myelodysplasia, Hematologic Malignancy
Related terms Anemia, Refractory, with Excess of Blasts, Hematologic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov